PhotoCure ASA's efforts to obtain U.S. approval for its Metvix photodynamic therapy as a treatment for basal-cell carcinoma hit another roadblock last week, as FDA officials ruled that the clinical data submitted in its new drug application were insufficient for approval. (BioWorld International) Read More
